Life Sciences and Healthcare

Trump targets drug prices – 5 implications for pharma

On July 24, 2020, President Trump signed several executive orders directing the secretary of Health and Human Services (HHS) to take steps to lower drug prices. The directive includes the following measures: 1. International pricing index The most aggressive policy directive tasks the HHS secretary with linking the price of Medicare prescription drugs to an […]

Securing the best price for an out-licensed asset

Biotech Ensysce seeks out-licensing or partnering opportunities around the world for its proprietary abuse and overdose resistant prodrug technologies. Learn how the company has made successful deals faster, without sacrificing due diligence, and negotiated a higher price than what it originally thought it could obtain.

Patient enrollment continues to be a limiting factor for trial durations

To prepare for our recent webinar “Trends in Clinical Trial Planning,” we dug into proprietary data from The Centre for Medicines Research (CMR) International, a wholly owned subsidiary of Clarivate working with leading global pharmaceutical companies to provide insights into industry trends — to strengthen R&D planning and effectiveness.   The length of clinical trials […]

Understanding disruptions to the antibiotic supply resulting from COVID-19

The COVID-19 pandemic has highlighted vulnerabilities within the generic drug supply chain. To minimize the effects of antibiotic API supply disruptions, it is important to understand the underlying reasons for shortages to then identify the best-fit manufacturing partners.   The COVID-19 pandemic has disrupted the global drug supply, as manufacturing companies contend with government-mandated or […]

Retail Giants Reshaping Primary-Care Focus

Walgreens $1 billion in-store physician model may improve patient outcomes A series of partnerships and developments sweeping through the convenient care sector this past year is causing major drugstore retailers CVS-Aetna, Walgreens and Walmart – along with payers Blue Cross Blue Shield and Humana – to battle for control over patients’ healthcare decisions. These patients […]

Conducting pathway analyses to accelerate discovery research

Discover how researchers at Harvard University freed up the bioinformatics team by empowering biologists to analyze their own data, and made critical go/no-go decisions regarding which drugs to push through the development lifecycle by obtaining an understanding of omics data in the context of their therapeutic area

Gaining insight with artificial intelligence

In part three of this blog series about best practices in toxicology, we continue the discussion from previous articles that outlined elements in the discovery stage that could impact safety, and considering a drug’s effects on toxicity of specific organs and specific patients via toxicogenomics, pharmacogenomics and pharmacoepigenomics. To help reach a deeper understanding of […]

Organ-specific toxicity and personalized approaches

In part two of this blog series about best practices in toxicology, we continue the discussion from the previous post, which described the aspects of drug discovery that could impact safety. Because safety can vary by person and organ, we also need to identify how we can determine a drug’s potential toxic effects on specific […]